Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Michiel Coppens, Steven W. Pipe, Wolfgang Miesbach, Jan Astermark, Michael Recht, Paul van der Valk, Bruce Ewenstein, Karen Pinachyan, Nicholas Galante, Sandra Le Quellec, Paul E. Monahan, Frank W.G. Leebeek, HOPE-B Investigators

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial'. Together they form a unique fingerprint.

Medicine and Dentistry